“We achieved encouraging results, knowledge and experience in vaccine development from our prior research collaboration with Sanofi Pasteur (which is anticipated to end in October 2016) that we believe can be leveraged and built upon with other partners. During the collaboration, meaningful improvements were made to the C1 expression system to produce antigens of interest that Sanofi further tested in mice trials. The mice trial data indicated that the C1 produced antigen generated an equal or better immune response in mice than the industry standard antigen.”
Jeffrey Edward Gundlach is a businessman, fund manager, and philanthropist. He is the founder of DoubleLine Capital, an investment firm.
On 11 November 2020, Gundlach remarked in an interview with...
